Amicus Therapeutics (FOLD) Earnings Date, Estimates & Call Transcripts $9.59 +0.07 (+0.74%) (As of 11/20/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amicus Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amicus Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataFOLD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.FOLD Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Brownstone ResearchBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate Amicus Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20243-$0.07-$0.06-$0.06 Q2 20243-$0.07-$0.01-$0.03 Q3 20243$0.01$0.03$0.02 Q4 20243$0.03$0.08$0.05 FY 202412-$0.10$0.04-$0.03 Q1 20251-$0.02-$0.02-$0.02 Q2 20251$0.01$0.01$0.01 Q3 20251$0.04$0.04$0.04 Q4 20251$0.10$0.10$0.10 FY 20254$0.13$0.13$0.13 Q1 20261$0.07$0.07$0.07 Q2 20261$0.08$0.08$0.08 Q3 20261$0.15$0.15$0.15 Amicus Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/26/2025(Estimated)------- 8/8/2024Q2 2024-$0.05-$0.05-$0.07$121.21M$126.67M 5/9/2024Q1 2024-$0.06-$0.02+$0.04$0.12$111.19M$110.40M 2/28/2024Q4 2023-$0.06-$0.11 -$0.05-$0.11$115.11M$115.08M 11/8/2023Q3 2023-$0.08-$0.07+$0.01-$0.07$102.30M$103.50M 8/8/2023Q2 2023-$0.12-$0.15 -$0.03-$0.15$89.57M$94.50M 5/10/2023Q1 2023-$0.13-$0.18 -$0.05-$0.18$82.14M$86.27M Get the Latest News and Ratings for FOLD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/1/2023Q4 2022-$0.13-$0.19 -$0.06-$0.19$86.95M$88.20M Amicus Therapeutics Earnings - Frequently Asked Questions When is Amicus Therapeutics's earnings date? Amicus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates. Learn more on FOLD's earnings history. What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics updated its FY 2024 earnings guidance on Wednesday, November, 6th. The company issued revenue guidance of $519.2 million-$527.2 million, compared to the consensus revenue estimate of $517.1 million. How much revenue does Amicus Therapeutics generate each year? Amicus Therapeutics (NASDAQ:FOLD) has a recorded annual revenue of $493.67 million. How much profit does Amicus Therapeutics generate each year? Amicus Therapeutics (NASDAQ:FOLD) has a recorded net income of -$151.58 million. FOLD has generated -$0.34 earnings per share over the last four quarters. What is Amicus Therapeutics's EPS forecast for next year? Amicus Therapeutics's earnings are expected to grow from ($0.05) per share to $0.20 per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Bausch Health Companies Earnings Date Arrowhead Pharmaceuticals Earnings Date Perrigo Earnings Date BridgeBio Pharma Earnings Date Biohaven Earnings Date Allakos Earnings Date Blueprint Medicines Earnings Date Exelixis Earnings Date Exact Sciences Earnings Date Repligen Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Bill Gates’s Next Big AI Bet: Stargate (Ad)In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate This page (NASDAQ:FOLD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
